medigraphic.com

2018, Number 1

<< Back

Rev Hosp Jua Mex 2018; 85 (1)

Antiretroviral-induced liver injury

Alonso-Bello CD; Reyes-Cetina IL; Delgado-Cortés HM; Martínez-Velázquez M, Arroyo-Mendoza ME

Language: Spanish
References: 20
Page: 49-56
PDF size: 301.15 Kb.


ABSTRACT

Introduction: Drug-induced liver injury (DILI), which accounts for 4-6% of adverse drug reactions and can lead to liver failure and death, can be caused by multiple drugs, dietary supplements, traditional Chinese medicines and other health products. Depending on the type of cells affected, it is classified into hepatocellular, cholestatic, hepatocellular-colestatic mixed type and vascular lesion. We present a case with the objective of reviewing current concepts of this entity. Clinical case: 31-year-old woman, no significant history, HIV serology negative, at the end of the fifth cycle of chemotherapy for Hodgkin’s lymphoma variant mixed cellularity. Presents clinical picture of atypical pneumonia, serology is determined for HIV1, which is positive, initiates treatment with tenofovir, emtricitabine and efavirenz, presents jaundice and alteration of liver function tests, is biopsied for liver biopsy that showed a drug-induced liver injury compatible outcome, decided to withdraw antiretroviral drug and reassessed for treatment change for HIV infection. Conclusions: DILI is a well-recognized entity; its timely diagnosis and treatment are indispensable to reverse the damage.


REFERENCES

  1. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89(6): 806-15.

  2. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 2015; 148(7): 1340-52.e7.

  3. Antonello VS, Kliemann DA, Rigel Santos B, Tovo CV. HAART and liver: is it safe? J Infect Dev Ctries 2014; 8(11): 1444-50.

  4. Aithal G. Drug-induced liver injury. Medicine 2015; 43(1): 590-3.

  5. Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 2014; 146(4): 914-28.

  6. Mosedale M, Watkins PB. Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther 2017; 101(4): 469-80.

  7. White KD, Chung WH, Hung SI, Mallal S, Phillips EJ. Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. J Allergy Clin Immunol 2015; 136(2): 219-34; quiz 235.

  8. Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol 2015; 12(7): 387-400.

  9. Kakisaka K, Kataoka K, Suzuki Y, Okada Y, Yoshida Y, Kuroda H et al. Necrotic cell death and suppression of T-cell immunity characterized acute liver failure due to drug-induced liver injury. Cytokine 2016; 86(1): 21-8.

  10. Fink DL, Bloch E. Liver transplantation for acute liver failure due to efavirenz hepatotoxicity: the importance of routine monitoring. Int J STD AIDS 2013; 24(10): 831-3.

  11. Surgers L, Lacombe K. Hepatoxicity of new antiretrovirals: a systematic review. Clin Res Hepatol Gastroenterol 2013; 37(2): 126-33.

  12. Mouton JP, Cohen K, Maartens G. Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen. Expert Rev Clin Pharmacol 2016; 9(11): 1493-503.

  13. Gish RG, Trinh H, Leung N, Chan FK, Fried MW, Wright TL, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 2005; 43(1): 60-6.

  14. Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006; 166(1): 49-56.

  15. Ortega-Alonso A, Stephens C, Lucena MI, Andrade RJ. Case characterization, clinical features and risk factors in drug-induced liver injury. Int J Mol Sci 2016; 17(5). pii: E714.

  16. Hayashi PH, Fontana RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin Liver Dis 2014; 34(2): 134-44.

  17. Goodman ZD. Phenotypes and pathology of drug-induced liver disease. Clin Liver Dis 2017; 21(1): 89-101.

  18. Ou P, Chen Y, Li B, Zhang M, Liu X, Li F, et al. Causes, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital. Springerplus 2015; 4: 802.

  19. Saithanyamurthi H, Faust AJ. Drug-induced liver disease: clinical course. Clin Liver Dis 2017; 21(1): 21-34.

  20. de Boer YS, Sherker AH. Herbal and dietary supplement-induced liver injury. Clin Liver Dis 2017; 21(1): 135-49.




2020     |     www.medigraphic.com